Bulk mixers of prescribed drugs get more scrutiny

November 18, 2013 by Matthew Perrone

Congress has taken a half step toward increasing federal oversight of so-called compounding pharmacies that custom mix medications in bulk, a year after a meningitis outbreak from contaminated pain injections killed at least 64 people and sickened hundreds of others.

The Senate approved the bill Monday by voice vote, sending it to President Barack Obama for his signature. The House passed the bill in September.

Last year's was traced to a now-closed pharmacy in Framingham, Mass., where inspectors found mold and other unsterile conditions.

Jurisdiction over large-volume compounders has been murky. Pharmacies are typically regulated by state boards, but the Food and Drug Administration regulates drug manufacturers. The gives the FDA authority to inspect large-volume compounders, but doesn't require them to register with the federal agency.

Explore further: House unveils bill to police specialty pharmacies

Related Stories

House unveils bill to police specialty pharmacies

September 13, 2013
(AP)—House lawmakers have introduced legislation that would bring more federal oversight to large specialty pharmacies like the one that triggered a deadly meningitis outbreak last year.

Senate questions pharmacy boards after outbreak

November 19, 2012
(AP)—A Senate committee investigating a deadly outbreak of meningitis wants to know how regulators in all 50 states oversee specialty pharmacies like the one that triggered the illness.

Congress investigating compounding trade group

December 7, 2012
(AP)—House lawmakers are investigating whether the industry group for compounding pharmacies coached the company responsible for a deadly outbreak of meningitis in dealing with regulators.

FDA chief renews push for specialty pharmacy rules

December 19, 2012
(AP)—The head of the Food and Drug Administration renewed her push for new rules to help police pharmacies like the one that triggered a deadly meningitis outbreak, even as members of Congress expressed little interest ...

Consumer watchdog asks FDA to revisit compounders

November 29, 2012
(AP)—A government watchdog group is calling on the Food and Drug Administration to re-inspect more than a dozen specialty pharmacies with prior records of violations, in light of a recent deadly outbreak tied to compounded ...

Mass. Gov. proposes new compounding pharmacy rules

January 4, 2013
(AP)—Gov. Deval Patrick is proposing tighter regulations on compounding pharmacies following last year's deadly meningitis outbreak linked to a Massachusetts company.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.